Smart bra set to detect breast cancer
A French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
Trilogue put lights on green for Horizon Europe
The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliaments proposal to increase its budget from €100bn to €120bn.
GARDP wants five AMR breakers by 2025
GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.
Sanifit raise €72.2m to push SNF472 development
Sanifit has bagged €72.2m in Spains largest private biotech fundraise.
Genfit in $228m deal with Terns Pharmaceuticals
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Vesalius Biocapital III Fund closes at €120 million
Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.
Erytech Pharma SA bags US$57m from SQZ Biotechnologies
Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies.
Sanofi/Regeneron’s IL-33 blocker meets endpoint in POC study
Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients.
Researchers and bioethicists to pause germline editing
After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.
Karo Pharma acquires Trimb AB
Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).